Advanced Search
Current and Breaking News for Professionals, Consumers and Media



Click here to learn how to advertise on this site and for ad rates.

FDA Approval Author: FDA Consumer Health Information Last Updated: Jan 25, 2013 - 3:31:45 PM



FDA Approves Over-the-Counter Oxytrol for Women to Treat Overactive Bladder

By FDA Consumer Health Information
Jan 25, 2013 - 3:28:53 PM



Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust


Email this article
 Printer friendly page

(HealthNewsDigest.com) - The U.S. Food and Drug Administration today approved Oxytrol for Women, the first over-the-counter treatment for overactive bladder in women ages 18 years and older.

Oxytrol will remain available for men with overactive bladder by prescription only.

Overactive bladder is a condition in which the bladder squeezes too often or squeezes without warning. Symptoms include leaking urine (urinary incontinence), feeling the sudden and urgent need to urinate, and frequent urination. Overactive bladder affects an estimated 33 million Americans, the majority of whom are older women.

Oxytrol for Women contains oxybutynin, a medicine that helps relax the bladder muscle. Oxybutynin belongs to a class of drugs known as anticholinergics. It is the first drug in this class to be made available over-the-counter for treatment of overactive bladder.

Oxytrol for Women is a patch that is applied to the skin every four days. The patch delivers 3.9 milligrams of oxybutynin per day.

"Studies demonstrate that over-the-counter Oxytrol for Women is a safe and effective treatment for overactive bladder," said Shaw Chen, M.D., Ph.D., deputy director of the Office of Drug Evaluation IV in the FDA's Center for Drug Evaluation and Research. "Women should make sure to follow the Drug Facts label and consult their doctor if their condition does not improve."

Oxytrol for Women's safety and effectiveness for over-the-counter use were established in more than 5,000 subjects participating in nine studies. Overall, results from these studies showed that consumers can understand the information on the label, properly select whether the product is right for them, and use the drug appropriately.

Side effects reported during clinical studies were mild and included skin irritation where the patch was applied, dry mouth and constipation. A leaflet with tips to help manage overactive bladder will be provided with the product.

Oxytrol for Women is marketed by Merck, based in Whitehouse Station, N.J.

For more information:

Understanding Over-the-Counter Medicines

The OTC Switch Process

###

 

For advertising and promotion on www.HealthNewsDigest.com contact Mike McCurdy at: tvmike13@healthnewsdigest.com  or call 877-634-9180. We are syndicated worldwide and read in 164 countries. We also have over 7,000 journalists as subscribers who may use our content for their own media!

 

 

 



Top of Page

HealthNewsDigest.com

FDA Approval
Latest Headlines


+ FDA Approves a New Silicone Gel-filled Breast Implant
+ FDA approves two drugs, companion diagnostic test for advanced skin cancer
+ FDA Approves New Drug for Advanced Prostate Cancer
+ U.S. Marshals Seize Food at New York-based Kosher Food Facility
+ Stimulant DMAA May Endanger Your Health, FDA Warns
+ FDA Issues Proposal to Improve the Quality of Automated Eternal Defibrillators
+ FDA Approves New Treatment for Late-stage Breast Cancer
+ FDA Approves Pomalyst for Advanced Multiple Myeloma
+ FDA Approval of Generic Version of Cancer Drug Doxil is Expected to Help Resolve Shortage
+ Beware of Fraudulent Flu Products



Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions